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In multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the absence of surrogate endpoints makes clinical
trials long and expensive. We aim to determine annualized whole-brain atrophy rates (a-WBAR) in idiopathic Parkinson’s disease
(IPD), MSA, and PSP. Ten healthy controls, 20 IPD, 12 PSP, and 8 MSA patients were studied using a volumetric MRI technique
(SIENA). In controls, the a-WBARwas 0.37%±0.28 (CI 95% 0.17–0.57), while in IPD a-WBARwas 0.54%±0.38 (CI 95% 0.32–0.68).
The IPD patients did not differ from the controls. In PSP, the a-WBAR was 1.26% ± 0.51 (CI 95%: 0.95–1.58). In MSA, a-WBAR
was 1.65% ± 1.12 (CI 95%: 0.71–2.59). MSA did not differ from PSP. The a-WBAR in PSP and MSA were significantly higher than
in the IPD group (𝑝 = 0.004 and 𝑝 < 0.001, resp.). In PSP, the use of a-WBAR required one-half of the patients needed for clinical
scales to detect a 50% reduction in their progression. In MSA, one-quarter of the patients would be needed to detect the same
effect. a-WBAR is a reasonable candidate to consider as a surrogate endpoint in short clinical trials using smaller sample sizes. The
confidence intervals for a-WBARmay add a potential retrospective application for a-WBAR to improve the diagnostic accuracy of
MSA and PSP versus IPD.
1. Introduction
There is a need to characterize disease progression in idio-
pathic Parkinson’s disease (IPD), multiple system atrophy
(MSA), and progressive supranuclear palsy (PSP) to test
the effectiveness of disease-modifying interventions. PSP
and MSA can be misdiagnosed with IPD or vice versa at
the initial stages of the disease and differential diagnosis
can be challenging, although a number of neuroimaging
techniques allow a partial distinction among the diseases
[1]. Clinical trials for these disorders are hampered by the
lack of surrogate endpoints and the unknown tempo of
neuronal destruction. While clinical scales have been largely
used to measure disease progression in therapeutic trials,
they have a number of inherent limitations that reduce
their sensitivity for tracking disease progression. They may
show nonlinearity, floor and ceiling effects, or an inability to
differentiate symptomatic changes from disease modification
changes. In addition there may be influences from other
disorders, behavioral fluctuations, and effects of medications
[2]. These factors may increase the variability of clinical data
and limit both their effectiveness as outcome measures and
their utility as inputs to power calculations when generating
sample size estimates for clinical trials.
Whole-brain atrophy rates (WBAR) from MRI data may
be an informative way to quantify disease progression in an
unbiased fashion, although to date, only three studies have
used such an approach in PSP andMSA [3–5].This approach
reduces interindividual variability in brain size andmorphol-
ogy when baseline scans are used as reference points so that
the subject acts as his or her own control.
In this study on LatinAmericanChilean patients, we used
the Structural Image Evaluation Using Normalization of
Atrophy (SIENA) [6, 7] to estimate a-WBAR (annualized
whole-brain atrophy rates) in IPD, PSP, and MSA. Further-
more, we determined the associations of a-WBAR with clini-
cal scales, explored the retrospective application of a-WBAR
to differentiate MSA and PSP from IPD, and reported sample
sizes per arm derived from these clinical and MRI measures
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Table 1: Baseline demographics, clinical features, and a-WBAR.
Controls
𝑁 = 10
IPD
𝑁 = 20
PSP
𝑁 = 12
MSA
𝑁 = 8
Group
comparisons
Significant pairwise
comparison
Age (years)a
Mean ± SD 64.6 ± 9.9 62.2 ± 11.5 69.9 ± 5.6 60.4 ± 10.9
𝐹 = 1.96
df = 3
𝑝 = 0.13
Gender (M : F)b 3 : 7 8 : 12 6 : 6 6 : 2
𝐹 = 4.1
df = 3
𝑝 = 0.25
Disease durationa (years)
Mean ± SD N/A 3.1 ± 3.3 2.2 ± 1.5 3.8 ± 3.6
𝐹 = 0.75
df = 2
𝑝 = 0.47
a-WBARa
(Mean ± SD plus 95%
confident interval)
0.37%± 0.28
(0.17–0.57)
0.54%± 0.38
(0.32–0.68)
1.26%± 0.51
(0.95–1.58).
1.65%± 1.12
(0.71–2.59).
𝐹 = 12
df = 3
𝑝 < 0.001
IPD versus MSA <
0.001
IPD versus PSP =
0.004
UPDRS IIIc
(median score plus range)
23.2 ± 12
(3–46)
37 ± 14.5
(20–62)
45.3 ± 13
(29–67)
𝜒
2
= 13
df = 2
𝑝 = 0.001
IPD versus MSA =
0.001
IPD versus PSP =
0.014
CGI-Sc
(median score plus range)
3.4 ± 0.6
(3–5)
4.4 ± 0.5
(4-5)
4.64 ± 0.5
(4-5)
𝜒
2
= 19
df = 2
𝑝 = 0.001
IPD versus MSA <
0.001
IPD versus PSP <
0.001
H&Yc
(median score plus range)
1.9 ± 0.6
(1.0–3.0)
2.6 ± 0.7
(2.0–4.0)
3.0 ± 0.8
(2.0–4.0)
𝜒
2
= 12
df = 2
𝑝 = 0.002
IPD versus MSA =
0.002
IPD versus PSP =
0.011
FABc 14.6 ± 3.5(5–18)
10.0 ± 5.3
(3–16)
12.0 ± 4.2
(4–16)
𝜒
2
= 7.8
df = 2
𝑝 = 0.016
IPD versus PSP = 0.08
MMSEc 26.9 ± 3.7(14–30)
20.9 ± 10
(3–30)
26.6 ± 2.5
(22–30)
𝜒
2
= 3.19
df = 2
𝑝 = 0.2
aANOVA test. bChi square test. cKruskal-Wallis test and post hoc procedure with Mann-Whitney test 𝑝 = 0.05/3 = 0.016. UPDRS III: Unified Parkinson’s
Disease Rating Scale Part III; H&Y: Hoehn and Yahr Scale; CGI-S: Clinical Global Impression for Disease Severity; FAB: Frontal Assessment Battery; a-WBAR:
annual whole-brain atrophy rates. MMSE: Mini-Mental State Examination.
for a hypothetical placebo-controlled disease-modifying trial
to estimate their relative utility as primary outcomes.
2. Materials and Methods
2.1. Subjects and Clinical Assessment. Fifty participants (10
healthy controls, 20 IPD, 12 PSP, and 8 MSA patients)
were recruited from the Movement Disorders Clinic at the
Hospital San Juan de Dios, Santiago, Chile. Internationally
established operational criteria were used to assess the diag-
noses of MSA, PSP, and IPD [8–10]. Fourteen IPD patients
had the tremor dominant phenotype and six had the postural
instability gait disorder phenotype. Of the 12 PSP patients,
eleven had the typical features of classic PSP (Richardson’s
syndrome) and one had an atypical profile with tremor
and moderate L-DOPA responsiveness (PSP-Parkinsonism
variant). Six probable MSA patients were categorised as
MSA-P (predominant parkinsonian features) and two as
MSA-C (predominant cerebellar features). All participants
were assessed on their usual dopaminergic medication and
the IPDpatientswere evaluated in the “on state.”Thepatients’
demographics and clinical variables are presented in Table 1.
The clinical parameters and correlations of a-WBAR with
clinical scales were explored using the 18 items of the
Movement Disorder Society-Sponsored Revision of the Uni-
fied Parkinson’s Disease Rating Scale (MDS-UPDRS) motor
symptoms (UPDRS III) [11, 12], Hoehn andYahr Scale (H&Y)
[13], and the Clinical Global Impression for Disease Severity
(CGI-S) [14]. The Mini-Mental State Examination (MMSE)
was used as a measure of general cognitive function [15].
Executive function was assessed using the Frontal Assess-
ment Battery (FAB) [16]. The mean time interval between
clinical assessments was 1.03 ± 0.08 years.
2.2.MRIAcquisition. Between 2012 and 2014, patients under-
went a MRI brain scan. MRI images were acquired on a
3.0 T Philips Medical System. Axial T
1
-weighted images of
the whole-brain were obtained using a 3D inversion recovery
prepared spoiled gradient echo (IR-SPGR) sequence. The
following parameters were used: repetition time of 8.1ms;
Parkinson’s Disease 3
echo time of 3.7ms; inversion time of 450ms; voxel size of
0.699 × 0.699 × 1mm; excitation flip angle of 8∘; matrix size
of 248 × 226; field of view of 24 cm; and 198 axial slice of
1mm. An experienced neuroradiologist (GG) assessed the
MRI scans of every patient to rule out gross anatomical
abnormalities. Patients underwent a second MRI brain scan
at the time of the last study visit (12 months after the baseline
scan). Subjects were included in the study if they had two
MRI scans of adequate quality and the brain extraction step
in SIENA functioned correctly. None of the MRI images
included in this study showed any structural abnormalities
other than atrophy-related changes. These inclusion criteria
were assessed by a visual inspection of the raw and processed
data for each patient scan. For both the baseline and the
follow-up assessments, the clinical data and MRI scans were
acquired within one week of each other.Themean scan inter-
val was 1.04 ± 0.07 years.
2.3. Data Analysis. All of the images were converted in
NIFTI format in preparation of processing using SIENA.
Before further processing, all of the data were anonymized
by removing any references to the patients’ names from the
image headers and ensuring that the file names were based
on a unique ID rather than any of the patients’ personal
details, including their clinical group. The SIENA process-
ing algorithm has been validated and described in detail
elsewhere [7]. Briefly, the processing stages are as follows:
(1) brain extraction (BET): segmentation of the brain from
nonbrain tissue for each scan, followed by skull extraction; (2)
registration: the segmented brain from the second (follow-
up) scan is registered to that of the first (baseline) using
a linear transformation; the two skull images are used as
normalizing factors to constrain the scale and skew; (3) tissue
type segmentation: white matter and grey matter tissues are
treated as one tissue and the cerebrospinal fluid as another;
(4) change analysis: in this step, the method detects the brain
edge on both registered brain images and then estimates the
motion of the brain surface edges.The direction ofmovement
from the first image to second image indicates whether
atrophy or growth has occurred. Finally, the percentage of
global brain volume change is obtained for each subject from
the mean of all of the edge point motions. SIENA has been
shown to have 0.5% brain volume accuracy in longitudinal
studies [6, 7].
2.4. Statistical Analyses. Statistical analyses of the clini-
cal data and clinical-imaging correlations were performed
using the Statistical Package for Social Sciences (SPSS, Inc.,
Chicago, IL, USA, version 22). The results are presented
as the mean ± SD. In all cases, a two-sided 𝑝 value of
<0.05 was considered significant. Visual inspection of the
data using histograms and QQ-plots was performed to check
for violations of the assumption of a normal distribution.
Levene’s test of equal variances was used to verify the
assumption of the homogeneity of variances. As a result of
these checks, parametric and nonparametric statistical tests
were used. One-way analysis of variance was performed
for normally distributed data (age at examination, disease
duration, and a-WBAR). The Tukey test was used to control
for multiple testing. Because disease severity and neuropsy-
chological measures were nonnormally distributed, they
were compared between groups using a Kruskal-Wallis test,
and when necessary, a post hoc procedure with Bonferroni
correction for multiples testing (𝑝 values were multiplied by
4) was used to compare the four disease groups. A 𝜒2 test for
homogeneity was used to compare the distribution of males
and females across groups. The a-WBAR was calculated by
dividing the WBAR values by the interscan interval in years.
Clinical scores were also annualized by dividing the unit
change between assessments by years. Changes in the clinical
scores were assessed using Wilcoxon’s signed rank test. The
associations between a-WBAR and annualized changes in
clinical scores were assessed using bivariate correlations and
simple linear regressions.
In each group, the sample size requirements to detect a
treatment difference per arm were estimated for a hypothet-
ical placebo-controlled disease-modifying trial. Annualized
changes in the clinical scores and a-WBAR were compared.
All of the calculations were based on the assumption of
a treatment effect corresponding to a small (20%) or a
moderate (50%) reduction in the annualized change in each
outcome measure, 90% power, and two-sided 0.05 level of
significance according to the standard formula:
sample size per trial arm: (𝑢 + V)2 ×
(2𝜎
2
)
(𝜇
1
− 𝜇
2
)
2
, (1)
where 𝑢 = 1.28 to provide 90% power, V = 1.96 to test at the
5% significance level, and 𝜇
1
and 𝜇
2
are the a-WBAR or mean
change in clinical scores in the placebo and treatment groups.
𝜎
2 is the commonvariance of the atrophy rate or of the clinical
score changes in both arms. The a-WBAR and changes in the
clinical scores were taken as the percentage of the difference
between the control and active groups.
2.5. Standard Protocol Approval, Registrations, and Patient
Consent. Prior to inclusion, patients gave their informed
written consent to participate in the study. The study was
conducted according to International Standards of Good
Clinical Practice (ICH guidelines and the Declaration of
Helsinki). The project was approved by the local Research
Ethics Committees of San Juan de Dios Hospital, Santiago,
Chile.
3. Results
3.1. Demographics, Clinical Variables, and a-WBAR (Table 1).
There were no significant differences in age, gender, and
disease duration between the groups. The PSP patients had
a shorter disease duration (2.2 ± 1.5 years). The PSP and
MSA patients showed greater impairment in the UPDRS III,
H&Y, and CGI-S than the IPD patients. The PSP patients
showed greater impairment on the cognitive measures than
the IPD patients. The IPD group did not show significant
overall clinical deterioration over the one-year follow-up
period, as did the MSA and PSP patients on the H&Y scale
and the MSA patients on the CGI-S scale (Table 2). Visual
inspection of the data indicated that some of the patients
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Table 2: Baseline, follow-up scores, and estimates of the sample sizes in PSP (𝑁 = 12) and MSA (𝑁 = 8).
Baseline score Repeat score Annual change
Number of subjects
required per arm
(20% reduction)
Number of subjects
required per arm
(50% reduction)
PSP
Whole-brain atrophy rate, % N/A† N/A† 1.26 ± 0.5 83 14
UPDRS III 37 ± 14.5 39.2 ± 19 2.3 ± 13 168 27
CGI-S 4.4 ± 0.5 4.6 ± 0.8 0.2 ± 0.6 4889 1048
H&Y 2.6 ± 0.7 3.3 ± 0.9∗ 0.7 ± 0.8 631 101
FAB 10 ± 5.3 10.7 ± 7.8 0.7 ± 4.6 22688 3630
MSA
Whole-brain atrophy rate, % N/A† N/A† 1.65 ± 1.1 234 38
UPDRS III 45.3 ± 13 52.6 ± 10 7.1 ± 9.4 921 148
CGI-S 4.6 ± 0.5 5.1 ± 3.5∗ 0.5 ± 0.5 621 100
H&Y 3.1 ± 0.8 3.7 ± 0.4∗ 0.7 ± 0.7 526 85
FAB 12.0 ± 4.2 10.8 ± 4.4 −1.1 ± 3.4 5020 804
∗Difference between the baseline and repeat score with a 𝑝 value < 0.05 (Wilcoxon’s signed rank test). †SIENA gives the whole-brain atrophy rate for image
pairs and does not estimate the baseline and follow-up brain volume. All of the values are the mean ± SD.
showed either improvement or unchanged values on clinical
measures (Figure 1). In contrast, all cases showed a brain
volume loss between scans. In the controls, a-WBAR was
0.37% ± 0.28 (CI 95% 0.17–0.57), and in IPD a-WBAR was
0.54% ± 0.38 (CI 95% 0.32–0.68). The IPD patients did not
differ from the controls.
In PSP, a-WBAR was 1.26% ± 0.51 (CI 95%: 0.95–1.58).
In MSA, the a-WBAR was 1.65% ± 1.12 (CI 95%: 0.71–2.59).
MSA did not differ from PSP. a-WBAR in the PSP and MSA
patients was significantly higher compared to the IPD group
(𝑝 = 0.004 and 𝑝 < 0.001, resp.) (Table 1, Figure 2).
3.2. Relationships between the Clinical Scores and a-WBAR.
No significant correlations were found between a-WBAR and
annualized clinical assessments in the three disease groups.
3.3. Sample Size Estimates. Table 2 (columns 5 and6) summa-
rizes the estimates of the sample size needed to detect small
(20%) or moderate (50%) reductions in the rates of a-WBAR
in response to treatment and similar annualized changes in
clinical scores. Using a-WBAR in PSP, 83 patients would be
required to detect a small treatment effect, and 14 patients
would be required to detect a moderate effect. In MSA, 234
and 38 patientswould be needed to detect small andmoderate
treatment effects, respectively. Using clinical measurements,
much larger patient cohorts would be required to detect
equivalent effects.
4. Discussion
The research of an early biomarker of disease progression
of atypical parkinsonisms is the main aim of this study. For
normal ageing, the a-WBAR has been estimated to be 0.3–
0.5% [4, 5, 17], as reported here (0.37%). In this longitudinal
study, we found an a-WBAR of 1.26% for PSP and 1.65%
for MSA, similar to previous reports [3–5]. In six autopsy-
confirmed PSP cases [4], the a-WBAR (measured using
the boundary shift integral (BSI) [18], a (semi)automated
technique similar to SIENA) was 1.3%. In another five proven
PSP cases, this figure was 1% [4, 5]; in another study, also
using BSI, a-WBAR estimates were approximately 1% for
both PSP and MSA based on 17 PSP cases and 9 cases with
MSA-P [3]. Consistent with previous reports, no significant
difference was observed in the current study between a-
WBAR in PSP and MSA [3].
It is plausible that cortical structures are the main con-
tributors to whole-brain atrophy in PSP and MSA. In PSP,
neuronal loss is recognized in frontal, temporal, and limbic
cortices and much less in parietal and occipital cortices
[19]. Such a neuronal loss is not considered to be typical in
MSA. However, Papp and Lantos described high densities
of glial cytoplasmic inclusions in the supplementary and
primary motor cortical areas and subjacent white matter
and moderate densities of glial cytoplasmic inclusions in the
premotor area, cingulate motor area, and corpus callosum in
MSA [20]. In a review of 203 provenMSA cases, some degree
of cortical atrophy was observed in 21% of cases [10], and
post mortem examinations showed severe frontal atrophy [21,
22]. In vivo data in MSA showed hypometabolism in motor,
premotor, and prefrontal cortices and parietal lobes [23].
A proton magnetic resonance spectroscopy study showed
a significant reduction of N-acetylaspartate/creatine in the
frontal cortex [24]. Voxel-based morphometry studies have
suggested that atrophy in the motor and prefrontal cortices is
a common finding in MSA [25].
In levodopa-responsive IPD patients, the evidence sup-
ports the idea that motor deficits predominantly relate to
the localized loss of selective dopaminergic neurons in the
substantia nigra, with cortical and subcortical grey and white
matter structures more preserved in comparison with those
of other Parkinsonian variants. In this study, the IPD patients
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Figure 1: Relationships between annual changes in H&Y scale (a) and UPDRS (b) versus a-WBAR in MSA and PSP groups: 8 patients with
brain atrophy showed either improvement (<0) or unchanged values (=0) on clinical measures.
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Figure 2: Error bars showing 95% confident intervals of a-WBAR
means for each group.
did not show abnormal a-WBAR; a-WBAR in IPDwas higher,
although still within normal limits, than previously reported
(0.28%). From a clinical perspective, PSP and MSA can be
misdiagnosed with IPD or vice versa at the initial stages
of the disease and differential diagnosis can be challenging
[26]. The confidence intervals for a-WBAR reported here
may add a potential retrospective application for a-WBAR
to improve the diagnostic accuracy for MSA and PSP versus
IPD, particularly in their initial stages, when the clinical
“plus syndrome” has not yet manifested and the response to
levodopa treatment is being assessed. Thus, a-WBAR within
a normal range is unlikely to be observed in PSP orMSA, but
is likely to be observed in IPD patients. However, before the
technique can be used to help to differentiate Parkinson plus
syndromes from IPD, a greater number of patients is needed
to establish a discriminatory cut-off point for these measures
and to estimate sensitivity, specificity, and positive predictive
values.
In MSA and PSP, the absence of surrogate endpoints
makes clinical trials even more difficult, long, and expensive.
For a biological marker to become a suitable surrogate
endpoint for clinical trials, it should not only have low
variability but also directly reflect any clinical benefit that
would be observed in the underlying measure it replaces
[27]. The variance in clinical scales as outcome measures is a
relevant problem when the need for fast and practical clinical
trials is pressing. Indeed, in both PSP andMSA (diseases that
are inevitably progressive), it is possible for clinical scores
to remain unchanged during the longitudinal assessment,
perhaps due to measurement error or the influence of
incidental factors on the patients’ status at the time of clinical
assessment. However, clinical assessment was performed in
“on state.”This point is important for monitoring the clinical
course of these diseases. Indeed, a number of patients showed
unchanged or improved clinical scores at the follow-up,
which is quite unusual for aggressive diseases as PSP orMSA.
The clinical scores might thus be influenced by medications
and did not reflect their real extent.
The relatively short clinical assessment interval in our
study may explain the absence of significant associations
between a-WBAR and changes in clinical scores [28, 29].
The variance in these clinical scales means that large patient
samples are required to detect small changes in outcomes.
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Conversely, every patient (in both groups) showed whole-
brain atrophy during the scan interval consistent with a
progressive neurodegenerative disorder. This indicates both
greater reliability and sensitivity for detecting markers of
degeneration using this MRI-derived measure compared to
clinical assessments.
The power analysis further addressed this point. In PSP,
the use of a-WBAR would require one-half of the patients
needed for UPDRS III to detect 50% of reduction in their
progression. In MSA, one-quarter of the patients would be
needed to detect the same effect. Because the objective of the
current power analysis was to compare the theoretical perfor-
mance of clinical and MRI-derived measures to track disease
progression in clinical trials, we did not correct for normal
ageing [30] and no allowancewasmade for patient dropout or
unusable scan pairs.These would have certainly increased the
sample size estimates, so the presentmeasurements should be
interpreted in light of these caveats. This approach does not,
however, impact the WBAR estimates and the variances that
we observed in both groups. Thus, the rate of brain volume
loss in a one-year period is a reasonable candidate to consider
as a potential surrogate endpoint.
SIENA offers several advantages compared with other
quantitativeMRI techniques, including a high reproducibility
of results and the capability to provide a robust measurement
of the global changes associated with disease conditions.
SIENA has also been shown to be robust to changes in
acquisition parameters, including the pulse sequence and
slice thickness [6]; this is an important advantage of clinical
trials, which are usually multicenter in nature.
The strength of this study consists in providing an early
biomarker of disease progression of atypical parkinsonisms,
which could be really helpful in future prospective studies
or clinical trials. These results are based on prospective
collection of clinical data with patients characterized in a
uniform manner and undergoing serial MRI imaging on the
same scanner.We acknowledge the relatively small number of
patients withMSA and the lack of pathological confirmation.
Another limitation of this this study is that we did not
include theProgressive Supranuclear Palsy (PSP)Rating Scale
[31] and the Unified Multiple System Atrophy Rating Scale
(UMSARS) [32], which are the standard clinical research
scales for those diseases.Themeasure used that comes closest
to a comprehensive scale for these diseases is the UPDRS
motor scale (UPDRS III). Factor analysis has revealed that
some items of UPDRS III are useful in assessing PSP patients:
axial and limb bradykinesia, tremor and rigidity, and face
and speech [12]. However, oculomotor, bulbar, autonomic,
and cerebellar domains are not included in UPDRS III. In
addition, the H&Y scale considers mild to moderate bilateral
disease and postural instability, which are early findings in
MSA and PSP. Therefore, when applied to MSA and PSP,
the latency to stage 3 is minimal and a “floor effect” is
evident; one study on pathological proven cases found that
92% of PSP and 67% of MSA patients reached stage 3 within
a year of motor onset [33]. Because of this, a Parkinson
plus syndrome may be suspected if a patient reaches stage 3
rapidly after the clinical onset [34]. Consequently, the scales
we report here do not fully assess the wide range of deficits
in MSA and PSP, and the clinical correlations we reported
can only provide information on parkinsonian symptoms
and cognitive functions, not to the entire clinical status of
patients. According to this, the lack of correlation between a-
WBAR and clinical scores may be explained. Secondly, this
methodological bias may have affected the power analysis
which requires a very high number of patients for diseases
having a prevalence of 4-5 cases/100.000.
In the future, it would therefore be beneficial to select
subscores of clinical scales that better highlight meaningful
associations between atrophy rates with the symptoms and
signs affecting MSA and PSP patients.
5. Conclusion
a-WBAR is more sensitive to disease progression than stan-
dard clinical assessments and can be reasonably considered
to be a potential surrogate endpoint in short and efficient
clinical trials using significantly smaller sample sizes. Finally,
a retrospective application for a-WBAR may help to differ-
entiate MSA and PSP versus IPD, particularly in their initial
stages.
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